ATE318615T1 - Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen - Google Patents

Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen

Info

Publication number
ATE318615T1
ATE318615T1 AT01972266T AT01972266T ATE318615T1 AT E318615 T1 ATE318615 T1 AT E318615T1 AT 01972266 T AT01972266 T AT 01972266T AT 01972266 T AT01972266 T AT 01972266T AT E318615 T1 ATE318615 T1 AT E318615T1
Authority
AT
Austria
Prior art keywords
inflammatory conditions
treat inflammatory
ppar delta
delta activator
activator
Prior art date
Application number
AT01972266T
Other languages
German (de)
English (en)
Inventor
Kevin William Buchan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE318615T1 publication Critical patent/ATE318615T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
AT01972266T 2000-10-05 2001-10-01 Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen ATE318615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0024361.8A GB0024361D0 (en) 2000-10-05 2000-10-05 Medicaments

Publications (1)

Publication Number Publication Date
ATE318615T1 true ATE318615T1 (de) 2006-03-15

Family

ID=9900709

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01972266T ATE318615T1 (de) 2000-10-05 2001-10-01 Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen

Country Status (9)

Country Link
US (1) US7084161B2 (https=)
EP (1) EP1324774B1 (https=)
JP (1) JP4106263B2 (https=)
AT (1) ATE318615T1 (https=)
AU (1) AU2001292046A1 (https=)
DE (1) DE60117584T2 (https=)
ES (1) ES2259675T3 (https=)
GB (1) GB0024361D0 (https=)
WO (1) WO2002028434A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
CA2449247A1 (en) * 2001-06-11 2002-12-19 Merck & Co., Inc. A method for treating inflammatory diseases by administering a ppar-delta agonist
EP1435946B8 (en) 2001-09-14 2013-12-18 Amgen Inc. Linked biaryl compounds
FR2836829B1 (fr) * 2002-03-11 2005-11-25 Bio Merieux Utilisation de l-alpha-lysophosphatidylcholine pour obtenir la differenciation de monocytes en cellules dendritiques matures in vitro
WO2005097098A2 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. Use of ppr delta agonists for treating demyelinating diseases
DE602005024384D1 (de) 2004-05-05 2010-12-09 High Point Pharmaceuticals Llc Neue verbindungen, ihre herstellung und verwendung
US8053598B2 (en) 2004-05-05 2011-11-08 High Point Pharmaceuticals, Llc Compounds, their preparation and use
WO2006020830A2 (en) 2004-08-12 2006-02-23 Amgen Inc. Bisaryl-sulfonamides
ES2372617T3 (es) 2005-06-30 2012-01-24 High Point Pharmaceuticals, Llc Ácidos fenoxiacéticos como activadores de ppar-delta.
CN103224477A (zh) 2005-12-22 2013-07-31 高点制药有限责任公司 作为PPAR-δ活化剂的苯氧基乙酸
US7943612B2 (en) 2006-03-09 2011-05-17 High Point Pharmaceuticals, Llc Compounds that modulate PPAR activity, their preparation and use
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
US8802705B2 (en) * 2007-05-21 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing PPAR delta agonist
AU2010282399A1 (en) * 2009-08-14 2012-03-01 Cerenis Therapeutics Holding S.A. Use of PPAR delta ligands for the treatment or prevention of inflammation or energy metabolism/production related diseases
KR102038866B1 (ko) * 2012-12-24 2019-10-31 서울대학교산학협력단 ＰＰＡＲδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도
EP3756661A1 (en) 2013-09-09 2020-12-30 vTv Therapeutics LLC Use of a ppar-delta agonist for treating muscle atrophy
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease
KR102750722B1 (ko) * 2022-03-16 2025-01-09 재단법인 대구경북첨단의료산업진흥재단 싸이아다이아졸 화합물 및 이를 포함하는 염증성 질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
AU8355998A (en) * 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
EP1324774A2 (en) 2003-07-09
AU2001292046A1 (en) 2002-04-15
DE60117584D1 (de) 2006-04-27
US7084161B2 (en) 2006-08-01
DE60117584T2 (de) 2006-12-21
EP1324774B1 (en) 2006-03-01
JP4106263B2 (ja) 2008-06-25
GB0024361D0 (en) 2000-11-22
US20050131035A1 (en) 2005-06-16
ES2259675T3 (es) 2006-10-16
JP2004510750A (ja) 2004-04-08
WO2002028434A3 (en) 2002-08-15
WO2002028434A2 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
ATE318615T1 (de) Verwendung von einem ppar delta aktivator zur behandlung von entzündlichen zuständen
WO2001081312A3 (en) Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore
Jackson et al. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases
ATE240744T1 (de) Verwendung von csf-1-inhibitoren
ATE404202T1 (de) Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
DE60035575D1 (de) Verwendubg von 3-hydroxy-3-methylglutaryl coenzym a reduktase inhibitoren zur herstellung eines medikaments zur behandlung der diabetischen neuropathie
ATE327753T1 (de) Carbonsäure-substituierte oxazol-derivate zur verwendung als ppar-alpha und -gamma aktivatoren zur behandlung von diabetes
DE60329316D1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
ATE192925T1 (de) Verwendung von inhibitoren des rezeptors der von blutplättchen abstammenden wachstumsfaktoren zur herstellung eines medikaments zur behandlung von krebserkrankungen
ATE468117T1 (de) Verwendung von 4- (4-thiazolyl)phenoxl alkoxy- benzamidinderivaten zur osteoporosebehandlung
RU2005108133A (ru) Дипептиднитрильные ингибиторы катепсина к
EA199900079A1 (ru) Способ получения фенильных гетероциклов, пригодных в качестве ингибиторов цог-2
DE60307237D1 (de) Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
ATE338575T1 (de) Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
ATE296827T1 (de) Heteropolycyclische inhibitoren
ATE402257T1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
ATE289196T1 (de) Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen
ES8305760A1 (es) Un procedimiento para la preparacion de derivados de oxazolidin-2,4-diona 5-heterociclico-sustituidos.
DE60323613D1 (de) Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
ATE369856T1 (de) Verfahren zur behandlung von glaukom
DE60124560D1 (de) Behandlung von angiogenesebezogenen krankheiten mit benzoyl phenylessigsäure derivaten
ATE430577T1 (de) Ppar delta-inhibitoren zur behandlung kardiovasculärer erkrankungen
ATE330596T1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
EP0906755A3 (en) Use of phenyl oxazole or phenyl thiazole derivatives for treating neuropathic pain
SE0103509D0 (sv) Rosuvastatin in pre demented states

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties